Gynecologic Clinical Trials

Meet the experts who make OSUCCC-James a nationally-recognized leader in cancer care and research.

Protocol No.PITitle
OSU-0495Barbara AndersenGynecologic Cancer Survivorship Survey
OSU-09091Floor BackesSurgical Staging in the Management of Endometrial Cancer
OSU-12114Floor BackesDetection of Sentinel Lymph Nodes in Patients with Endometrial Cancer Undergoing Robotic-Assisted Staging: Comparison of Isosulfan Blue and Indocyanine Green Dyes with Fluorescence Imaging
OSU-0499David CohnTissue, Serum and Data Acquisition Activity for the Study of Gynecologic Disease.
OSU-08096David CohnChemoFX Observational Study A Non-Interventional, Longitudinal, Multi-Center Initiative Examining Outcomes Associated with the Use of ChemoFX Assay in Solid tumor Malignancies
OSU-09008David CohnEvaluation of the Feasibility of Intrauterine Progesterone for the Treatment of Complex Atypical Hyperplasia and Low-grade Endometrial Cancer
OSU-12241David CohnCompassionate Use Protocol : International, multicenter, open-label, treatment-extension study for subjects who completed a Phase 1 or Phase 2 parental study to continue receiving treatment with SAR245408 or SAR245409 as a monotherapy or as a combination regimen
OSU-14015David CohnOvarian Cancer Patient-Centered Decision Aid
OSU-13232David CohnCompassionate Use Protocol:ABT-888 FOR A SINGLE PATIENT WITH RECURRENT,PLATINUM RESISTANT OVARIAN CANCER.THE PATIENT HAS BRCA MUTATION.
OSU-14139David CohnSociety of Gynecologic Oncology Clinical Outcomes Registry
OSU-12048Larry CopelandClinical and Pathologic Outcomes Related to the Genetic and Proteomic Expression in Endometrial Cancer
OSU-13005Brian FochtLifestyle Interventions to Improve Physical Function and Quality of Life in Endometrial Cancer Survivors: The Role of both Aerobic and Yoga based Exercise Programs
OSU-13257John HaysA Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
OSU-13151John HaysRandomized phase II study of intravenous 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine® NSC #663249) cisplatin-radiochemotherapy versus intravenous cisplatin-radiochemotherapy in women diagnosed with stage IB-IVA cervical cancer and stage II-IVA vaginal cancer
RTOG-0724Douglas MartinPhase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy.
GOG-9923David O'MalleyA Phase I Study of Carboplatin/Paclitaxel/CTEP-Supplied Agent Bevacizumab [NSC #704865, IND #7921] and CTEP-Supplied Agent ABT-888 [NSC #737664, IND #77840] in Newly Diagnosed Patients with Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
GOG-0264David O'MalleyA Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
OSU-12038David O'MalleyRandomized Phase II Evaluation of Carboplatinipaclitaxel with and without Trastuzumab (Herceptin®) in Her2/Neu+ Patients with Advancedirecurrent Uterine Serous Papillary Carcinoma
GOG-0277David O'MalleyA PHASE III RANDOMIZED TRIAL OF GEMCITABINE (NSC# 613327) PLUS DOCETAXEL (NSC# 628503) FOLLOWED BY DOXORUBICIN (NSC# 123127) VERSUS OBSERVATION FOR UTERUS-LIMITED, HIGH-GRADE UTERINE LEIOMYOSARCOMA
GOG-0275David O'MalleyA PHASE III RANDOMIZED TRIAL OF PULSE ACTINOMYCIN-D VERSUS MULTI-DAY METHOTREXATE FOR THE TREATMENT OF LOW-RISK GESTATIONAL TROPHOBLASTIC NEOPLASIA
GOG-213David O'MalleyPhase III Randomized Controlled Clinical Trial of Carboplatin & Paclitaxel in Combination w/ Bevacizumab followed by Bevacizumab & Secondary Cytoreductive Surgery in Platinum-sensitive Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
GOG-0274David O'MalleyA Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIAL
GOG-0238David O'MalleyA Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
OSU-13218David O'MalleyRandomized controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer
GOG-0229ODavid O'MalleyA Randomized Phase II Study with a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination with GSK2141795, an AKT Inhibitor, in Patients with Recurrent or Persistent Endometrial Cancer
OSU-13059David O'MalleyA Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults with Ovarian Cancer and other FOLR1-Positive Solid Tumors
OSU-13066David O'MalleyThe MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician¿s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
OSU-13140David O'MalleyA Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
OSU-13148David O'MalleyA Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
OSU-13259David O'MalleyA Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
OSU-13261David O'MalleyEvaluation of AminoIndexTM (Amino Metabolomic) As Biomarkers for Gynecologic Cancer Detection in the U. S. Population
GOG-0270David O'MalleyGROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) II: An observational study
GOG-0225David O'MalleyCan Diet and Physical Activity Modulate Ovarian Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
GOG-0279David O'MalleyA PHASE II TRIAL EVALUATING CISPLATIN (NSC #119875) AND GEMCITABINE (NSC # 613327) CONCURRENT WITH INTENSITY-MODULATED RADIATION THERAPY (IMRT) IN THE TREATMENT OF LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE VULVA
GOG-0286BDavid O'MalleyA Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
GOG-0278David O'MalleyEvaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for STAGE IA1 (LVSI+) and IA2-IB1 (¡Ü 2CM) Cervical Cancer
GOG-0263David O'MalleyRandomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation In Intermediate Risk, Stage I/IIa Cervical Cancer Treated With Initial Radical Hysterectomy And Pelvic Lymphadenectomy
GOG-0283David O'MalleyA Phase II Trial of DCTD-Sponsored Dasatinib (NSC #732517 IND #120636) in Recurrent /Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression
OSU-10096Electra PaskettCommunity Awareness, Resources and Education (CARE) II Project 3
OSU-11115Electra PaskettCOMMUNITY AWARENESS, RESOURCES AND EDUCATION (CARE II): PROJECT 4 THE PARENT (PARENTS IN APPALACHIA RECEIVE EDUCATION NEEDED FOR TEENS) PROJECT
OSU-13233Paul ReiterFocus Groups to Inform the Development of Interventions to Reduce Cervical Cancer among African American Women
OSU-07014Amanda TolandGenetic Modifiers of Breast and Ovarian Cancer Risk
OSU-10095Christopher WeghorstCommunity Awareness, Resources and Education (CARE II) Project: Project 1

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu